

CHAPTER 1 EXECUTIVE SUMMARY

Scope of the analysis

Datamonitor insight into the cardiovascular market

Related reports

Upcoming reports

CHAPTER 2 MARKET OVERVIEW AND DYNAMICS

Seven major markets

Regional markets

US

Japan

Five major EU markets

Cardiovascular and metabolic markets by disease area

Seven major markets

Regional markets

US

Japan

Five major EU market

Disease focus by mechanism of action

Diabetes

US

Japan

Five major EU markets

Dyslipidemia

US

Japan

Five major EU markets

Hypertension

US

Japan

Five major EU markets

Thrombosis

US

Japan

Five major EU markets

CHAPTER 3 MARKET FORECASTS

Seven major markets

Regional markets

US

Japan

Five major EU markets

Cardiovascular and metabolic market by disease area

Seven major markets

Regional markets

US

Japan

Five major EU markets

Disease focus by mechanism of action

Diabetes

US
Japan
Five major EU markets
Dyslipidemia
US
Japan
Five major EU markets
Hypertension
US
Japan
Five major EU markets
Thrombosis
US
Japan
Five major EU markets

CHAPTER 4 MARKET ANALYSIS

Leading cardiovascular and metabolic brands
Leading cardiovascular and metabolic active agents
Company portfolio assessment
The top 10 cardiovascular and metabolic companies, 2008
Pfizer
Sanofi-Aventis
Merck-Schering-Plough
Novartis
Bristol-Myers Squibb
Takeda
AstraZeneca
Novo Nordisk
Daiichi Sankyo
Abbott
Geographical distribution
Company vulnerability
The forecast top 10 cardiovascular and metabolic companies, 2005-2018

BIBLIOGRAPHY

APPENDIX A - MARKET ASSUMPTIONS

Data definitions, limitations and assumptions
Standard units
Japanese market data
Derivation of sales forecasts and pricing trends
Forecasts
Forecast methodology
Datamonitor reports

APPENDIX B - MARKET FORECAST DATA

Seven major markets
Regional markets
US
Japan
Five major EU markets

France
Germany
Italy
Spain
UK

APPENDIX C

Report methodology
About Datamonitor
About Datamonitor Healthcare
Disclaimer

List of Tables

- Table 1: Cardiovascular and metabolic revenues in the five major EU markets (\$m), 2005-08
Table 2: Top 25 cardiovascular and metabolic brands in the seven major markets, 2005-2018
Table 3: Top 25 cardiovascular and metabolic active agents in the seven major markets, 2005-2018
Table 4: Sales forecast for the major cardiovascular and metabolic brands and active agents in the seven major markets (\$000s), 2008-2018
Table 5: Sales forecast for the major cardiovascular and metabolic brands and active agents in the US (\$000s), 2008-2018
Table 6: Sales forecast for the major cardiovascular and metabolic brands and active agents in Japan (\$000s), 2008-2018
Table 7: Sales forecast for the major cardiovascular and metabolic brands and active agents in the five major EU markets (\$000s), 2008-2018
Table 8: Sales forecast for the major cardiovascular and metabolic brands and active agents in France (\$000s), 2008-2018
Table 9: Sales forecast for the major cardiovascular and metabolic brands and active agents in Germany (\$000s), 2008-2018
Table 10: Sales forecast for the major cardiovascular and metabolic brands and active agents in Italy (\$000s), 2008-2018
Table 11: Sales forecast for the major cardiovascular and metabolic brands and active agents in Spain (\$000s), 2008-2018
Table 12: Sales forecast for the major cardiovascular and metabolic brands and active agents in the UK (\$000s), 2008-2018

List of Figures

- Figure 1: Cardiovascular and metabolic sales (\$ billion) and standard units (SU) sold in the seven major markets, 2005-08
Figure 2: Total cardiovascular sales and sales growth in the seven major markets (\$ billion), 2005-08
Figure 3: Geographical distribution of cardiovascular sales in the seven major markets by value, 2005-08
Figure 4: Geographical distribution of cardiovascular units sold (SU) in the seven major markets by volume, 2005-08
Figure 5: Total cardiovascular sales and sales growth in the US, 2005-08
Figure 6: Total cardiovascular sales and sales growth in Japan (\$ billion), 2005-08
Figure 7: Total cardiovascular sales and sales growth in the five major EU market (\$ billion), 2005-08
Figure 8: Cardiovascular and metabolic sales in the seven major markets by disease area, 2008
Figure 9: Cardiovascular and metabolic standard units (SU) sold in the seven major markets by disease area, 2008
Figure 10: Cardiovascular and metabolic sales in the US (\$ billion) by disease area, 2005-08
Figure 11: Cardiovascular and metabolic sales in Japan (\$ billion) by disease area, 2005-08

Figure 12: Cardiovascular and metabolic sales in the five major EU markets (\$ billion) by disease area, 2005-08

Figure 13: Cardiovascular and metabolic sales in France (\$ billion) by disease area, 2005-08

Figure 14: Cardiovascular and metabolic sales in Germany (\$ billion) by disease area, 2005-08

Figure 15: Cardiovascular and metabolic sales in Italy (\$ billion) by disease area, 2005-08

Figure 16: Cardiovascular and metabolic sales in Spain (\$ billion) by disease area, 2005-08

Figure 17: Cardiovascular and metabolic sales in the UK (\$ billion) by disease area, 2005-08

Figure 18: Diabetes sales (\$ billion) by leading mechanism of action in the seven major markets, 2005-08

Figure 19: Diabetes standard units (SU) sold by leading mechanism of action in the seven major markets, 2005-08

Figure 20: Diabetes sales (\$ billion) by leading mechanism of action in the US, 2005-08

Figure 21: Diabetes standard units (SU) sold by leading mechanism of action in the US, 2005-08

Figure 22: Diabetes sales (\$ billion) by leading mechanism of action in Japan, 2005-08

Figure 23: Diabetes standard units (SU) sold by leading mechanism of action in Japan, 2005-08

Figure 24: Diabetes sales (\$ billion) by leading mechanism of action in the five major EU markets, 2005-08

Figure 25: Diabetes standard units (SU) sold by leading mechanism of action in the five major EU markets, 2005-08

Figure 26: Dyslipidemia sales (\$ billion) by leading mechanism of action in the seven major markets, 2005-08

Figure 27: Dyslipidemia volume use (SU units sold) by leading mechanism of action in the seven major markets, 2005-08

Figure 28: Dyslipidemia sales (\$ billion) by leading mechanism of action in the US, 2005-08

Figure 29: Dyslipidemia standard units (SU) sold by leading mechanism of action in the US, 2005-08

Figure 30: Dyslipidemia sales (\$ billion) by leading mechanism of action in Japan, 2005-08

Figure 31: Dyslipidemia standard units (SU) sold by leading mechanism of action in Japan, 2005-08

Figure 32: Dyslipidemia sales (\$ billion) by leading mechanism of action in the five major EU markets, 2005-08

Figure 33: Dyslipidemia standard units (SU) sold by leading mechanism of action in the five major EU markets, 2005-08

Figure 34: Hypertension sales (\$ billion) by leading mechanism of action in the seven major markets, 2005-08

Figure 35: Hypertension standard units (SU) sold by leading mechanism of action in the seven major markets, 2005-08

Figure 36: Hypertension sales (\$ billion) by leading mechanism of action in the US, 2005-08

Figure 37: Hypertension standard units (SU) sold by leading mechanism of action in the US, 2005-08

Figure 38: Hypertension sales (\$ billion) by leading mechanism of action in Japan, 2005-08

Figure 39: Hypertension standard units (SU) sold by leading mechanism of action in Japan, 2005-08

Figure 40: Hypertension sales (\$ billion) by leading mechanism of action in the five major EU markets, 2005-08

Figure 41: Hypertension standard units (SU) sold by leading mechanism of action in the five major EU markets, 2005-08

Figure 42: Antithrombotic sales (\$ billion) by leading mechanism of action in the seven major markets, 2005-08

Figure 43: Antithrombotic standard units (SU) sold by leading mechanism of action in the seven major markets, 2005-08

Figure 44: Antithrombotic sales (\$ billion) by leading mechanism of action in the US, 2005-08

Figure 45: Antithrombotic standard units (SU) sold by leading mechanism of action in the US, 2005-08

Figure 46: Antithrombotic sales (\$ billion) by leading mechanism of action in Japan, 2005-08

Figure 47: Antithrombotic standard units (SU) sold by leading mechanism of action in Japan, 2005-08

Figure 48: Antithrombotic sales (\$ billion) by leading mechanism of action in the five major EU markets, 2005-08

Figure 49: Antithrombotic standard units (SU) sold by leading mechanism of action in the five major EU markets, 2005-08

Figure 50: Forecast cardiovascular and metabolic sales (\$ billion) and standard units (SU) sold in the seven major markets, 2008-2018

Figure 51: Forecast total cardiovascular and metabolic sales (\$ billion) and sales growth in the seven major markets, 2008-2018

Figure 52: Geographical distribution of forecast cardiovascular and metabolic sales in the seven major markets, 2008-2018

Figure 53: Geographical distribution of forecast cardiovascular and metabolic units sold in the seven major markets, 2008-2018

Figure 54: Forecast cardiovascular and metabolic sales (\$ billion) and sales growth in the US, 2008-2018

Figure 55: Total forecast cardiovascular and metabolic sales (\$ billion) and sales growth in Japan, 2008-2018

Figure 56: Forecast cardiovascular and metabolic sales (\$ billion) and sales growth in the five major EU markets, 2008-2018

Figure 57: Forecast cardiovascular and metabolic sales in the seven major markets by disease area, 2018

Figure 58: Forecast cardiovascular and metabolic volume use (SU units sold) in the seven major markets by disease area, 2018

Figure 59: Forecast cardiovascular and metabolic sales (\$ billion) in the US by disease area, 2008-2018

Figure 60: Forecast cardiovascular and metabolic sales (\$ billion) in Japan by disease area, 2008-2018

Figure 61: Forecast cardiovascular and metabolic sales (\$ billion) in the five major EU markets by disease area, 2008-2018

Figure 62: Forecast cardiovascular and metabolic sales (\$ billion) in France by disease area, 2008-18

Figure 63: Forecast cardiovascular and metabolic sales (\$ billion) in Germany by disease area, 2008-2018

Figure 64: Forecast cardiovascular and metabolic sales in Italy (\$ billion) by disease area, 2008-2018

Figure 65: Forecast cardiovascular and metabolic sales (\$ billion) in Spain by disease area, 2008-2018

Figure 66: Forecast cardiovascular and metabolic sales (\$ billion) in the UK by disease area, 2008-2018

Figure 67: Diabetes sales and volume growth by leading mechanism of action in the seven major markets, 2005-08 and 2008-2018

Figure 68: Diabetes sales and volume growth by leading mechanisms of action in the US, 2005-08 and 2008-2018

Figure 69: Diabetes sales and volume growth by leading mechanism of action in Japan, 2005-08 and 2008-2018

Figure 70: Diabetes sales and volume growth by leading mechanism of action in the five major EU markets, 2005-08 and 2008-2018

Figure 71: Dyslipidemia sales and volume growth by leading mechanism of action in the seven major markets, 2005-08 and 2008-2018

Figure 72: Dyslipidemia sales and volume growth by leading mechanism of action in the US, 2005-08 and 2008-2018

Figure 73: Dyslipidemia sales and volume growth by leading mechanism of action in Japan, 2005-08 and 2008-2018

Figure 74: Dyslipidemia sales and volume growth by leading mechanism of action in the five major EU markets, 2005-08 and 2008-2018

Figure 75: Hypertension sales and volume growth by leading mechanism of action in the seven major markets, 2005-08 and 2008-2018

Figure 76: Hypertension sales and volume growth by leading mechanism of action in the US, 2005-08 and 2008-2018

Figure 77: Hypertension sales and volume growth by leading mechanism of action in Japan, 2005-08 and 2008-2018

Figure 78: Hypertension sales and volume growth by leading mechanism of action in the five major EU markets, 2005-08 and 2008-2018

Figure 79: Antithrombotic sales and volume growth by leading mechanism of action in the seven major markets, 2005-08 and 2008-2018

Figure 80: Antithrombotic sales and volume growth by leading mechanism of action in the US, 2005-08 and 2008-2018

Figure 81: Antithrombotic sales and volume growth by leading mechanism of action in Japan, 2005-08 and 2008-2018

Figure 82: Antithrombotic sales and volume growth by leading mechanism of action in the five major EU markets, 2005-08 and 2008-2018

Figure 83: Top 10 cardiovascular and metabolic brands in the seven major markets by sales, 2005-2018

Figure 84: Decline of the top 10 and top 25 cardiovascular and metabolic brands by sales (\$ billion) in the seven major markets, 2005-2018

Figure 85: Top 10 cardiovascular and metabolic active agents in the seven major markets by sales, 2005-2018

Figure 86: Decline in sales of the top 10 and top 25 cardiovascular and metabolic active agents in the seven major markets, 2005-2018

Figure 87: Geographical distribution of sales (\$ billion) of the top 10 cardiovascular and metabolic companies, 2008

Figure 88: Vulnerability of top 10 cardiovascular and metabolic companies by sales (\$ billion) in the seven major markets, 2005-08

Figure 89: Cardiovascular and metabolic franchise distribution of the top 10 companies by sales (\$ billion) in the seven major markets, 2008

Figure 90: Top 10 cardiovascular and metabolic companies in the seven major markets by sales, 2005-2018

Figure 91: Forecast branded cardiovascular and metabolic revenues (\$ billion) for the top 10 companies in the seven major markets, 2008-2018

Figure 92: Forecast branded cardiovascular and metabolic revenues (\$ billion) of AstraZeneca, Bristol-Myers Squibb, Novo Nordisk and Pfizer in the seven major markets, 2008-2018

Figure 93: Forecast branded cardiovascular and metabolic revenues (\$ billion) for Sanofi-Aventis and Merck-Schering-Plough in the seven major markets, 2008-2018